Table 1 Demographics and clinical characteristics of study subjects.

From: Disrupted structural network of inferomedial temporal regions in relapsing–remitting multiple sclerosis compared with neuromyelitis optica spectrum disorder

 

MS (n = 68)

NMOSD (n = 50)

HC (n = 26)

p value

Sex, N of females (%)

51 (75.0)

42 (84.0)

21 (80.8)

0.481a

Age, years, mean ± SD

34.7 ± 8.7

44.4 ± 11.6

35.3 ± 11.3

 < 0.001b

Disease duration, years, median (IQR)

3.9 (1.725–7.275)

2.75 (1.175–12.075)

NA

0.467

AQP4-IgG positivity, N (%)

0 (0)

45 (90.0)

NA

 < 0.001

Attack numbers, median (IQR)

2 (1–4)

3 (2–5)

NA

0.129

Anytime involvementc, N (%)

NA

 

Cerebral hemisphere

68 (100)

22 (44.0)

 

 < 0.001

Brainstem/cerebellum

44 (64.7)

23 (46.0)

 

0.043

Spinal cord

52 (76.5)

38 (76.0)

 

0.953

Optic nerve

27 (39.7)

28 (56.0)

 

0.080

EDSS, median (IQR)

1 (0–2.0)

2.5 (1.5–6.0)

NA

 < 0.001

Use of drugsd, N (%)

57 (83.8)e

45 (90.0)f

NA

0.333

  1. MS multiple sclerosis, NMOSD neuromyelitis optica spectrum disorder, HC healthy control, EDSS expanded disability status scale, IQR interquartile range, NA not applicable.
  2. ap value from chi-squared test.
  3. bp value from ANOVA, posthoc tests results: MS vs. NMOSD (p < 0.001), HC vs. NMOSD (p = 0.004), and MS vs. HC (p > 0.05).
  4. cSymptomatic involvement.
  5. dTaken at the time of brain MRI.
  6. eInterferon β-1b (n = 24), interferon β-1a (n = 11), teriflunomide (n = 8), azathioprine (n = 5), fingolimod (n = 3), glatiramer acetate (n = 3), dimethyl fumarate (n = 2), mitoxantrone (n = 1).
  7. fAzathioprine (n = 29), mycophenolate mofetil (n = 12), rituximab (n = 2), cyclosporine (n = 1), methotrexate (n = 1).
Back to article page